Kundel Yulia, Cohen Zoya, Gordon Noa, Sulkes Aaron, Morgenstern Sara, Perl Gali, Wasserberg Nir, Groshar David, Bernstine Hanna, Brenner Baruch
Institute of Oncology, Rabin Medical Center, Beilinson Hospital, Petah Tiqva, Israel.
Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Radiat Oncol. 2025 Aug 1;20(1):121. doi: 10.1186/s13014-025-02703-x.
Neoadjuvant (preoperative) radiochemotherapy (nRCT) is a standard of care in locally advanced rectal cancer (LARC). Several studies have shown that the decline in FDG uptake after 2 weeks of nRCT compared with the baseline, i.e. the tumor's metabolic response, may correlate with histopathological response. However, our previous prospective study suggested that the tumor's histopathological response could be predicted by the metabolic response already observed after 1 week of nRCT. The current study was undertaken to validate these findings.
Thirty-eight patients with LARC who received standard nRCT followed by radical surgery were enrolled. Metabolic response, evaluated by the percent of change in maximum standardized uptake value (ΔSUVmax%), measured by PET-CT imaging at baseline and on day 8 of nRCT, was compared with the histopathological response at surgery. Histopathological response was assessed by pathological complete response (pCR) and, when possible, by tumor regression grade (TRG). We also examined the association of baseline and second PET-CT parameters with pCR and TRG at surgery.
0239-07-RMC, registration date: 21/08/2007.
Neither pCR nor TRG were associated with any change in PET-CT parameters after 1 week of treatment. Baseline metabolic tumor volume (MTV) was the only PET-CT parameter with a statistically significant association with pCR (p = 0.002), but not with TRG (p = 0.08).
A decrease in SUVmax after 1 week of nRCT for LARC failed to predict the achievement of pCR or TRG in the post-nRCT surgical specimen, underlining the importance of validation clinical trials. Nonetheless, our findings on the correlation between baseline MTV and histopathological response can, if confirmed, be a useful tool for treatment selection. Validation in a larger independent cohort is planned.
新辅助(术前)放化疗(nRCT)是局部晚期直肠癌(LARC)的标准治疗方法。多项研究表明,与基线相比,nRCT 2周后氟代脱氧葡萄糖摄取量的下降,即肿瘤的代谢反应,可能与组织病理学反应相关。然而,我们之前的前瞻性研究表明,nRCT 1周后观察到的代谢反应即可预测肿瘤的组织病理学反应。本研究旨在验证这些发现。
纳入38例接受标准nRCT后行根治性手术的LARC患者。通过PET-CT成像在基线和nRCT第8天测量最大标准化摄取值变化百分比(ΔSUVmax%)来评估代谢反应,并与手术时的组织病理学反应进行比较。组织病理学反应通过病理完全缓解(pCR)评估,如有可能,还通过肿瘤退缩分级(TRG)评估。我们还研究了基线和第二次PET-CT参数与手术时pCR和TRG的相关性。
0239-07-RMC,注册日期:2007年8月21日。
治疗1周后,pCR和TRG均与PET-CT参数的任何变化无关。基线代谢肿瘤体积(MTV)是唯一与pCR有统计学显著相关性的PET-CT参数(p = 0.002),但与TRG无关(p = 0.08)。
LARC患者nRCT 1周后SUVmax的降低未能预测nRCT后手术标本中pCR或TRG的实现,强调了验证性临床试验的重要性。尽管如此,我们关于基线MTV与组织病理学反应之间相关性的发现,若得到证实,可为治疗选择提供有用工具。计划在更大的独立队列中进行验证。